Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;31(11):1629-1630.
doi: 10.1038/eye.2017.122. Epub 2017 Jun 16.

Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema

V E Konidaris  1 , K T Tsaousis  1 , Z Al-Hubeshy  1 , K Pieri  1 , J Deane  1 , T Empeslidis  1
Affiliations

Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema

V E Konidaris et al. Eye (Lond). 2017 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Change in mean BCVA (a) and CRT (b) at three time points: at presentation, before switching, and at 24 weeks after switching treatment to aflibercept. Statistically significant difference in BCVA and CRT was observed between various time points: presentation, before switching, and after switching treatment (P=0.008 and P<0.001, respectively).
Figure 2
Figure 2
Correlations between CRT and BCVA at three time points. A statistically significant correlation between BCVA and CRT at presentation (rp=0.565), and before switching (rp=0.565) was noted. However, there was no significant correlation between the BCVA and CRT after switching treatment (rp=−0.138).
See this image and copyright information in PMC

References

    1. Lim LS, Ng WY, Mathur R, Wong D, Wong EY, Yeo I et al. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol 2015; 9: 1715–1718. - PMC - PubMed
    1. Wood EH, Karth PA, Moshfeghi DM, Leng T. Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 950–954. - PubMed
    1. Shah CP, Heier JS. Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 836–839. - PubMed